Literature DB >> 25081289

Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study.

J W Han1, J S Yoon2, S Y Jang1.   

Abstract

PURPOSE: Long-standing prosthetic eye wearing induces ocular surface inflammation. We investigated the short-term effects of topical cyclosporine A 0.05% (Restasis) in patients with ocular discomfort resulting from long-standing prosthetic eye wearing.
METHODS: This was a prospective, interventional case series. Patients who were unilateral prosthetic eye wearers over a period of 5 years were enrolled at a single institution from March to July 2013. The subjects were instructed to instill topical cyclosporine A 0.05% twice per day. Measurements were made pre-treatment and after 1 and 3 months of treatment. Outcome measures were the ocular symptom score, the lid margin abnormality score, the Schirmer test, and the tear meniscus amount, using Fourier-domain optical coherence tomography.
RESULTS: In total, 20 consecutive patients (mean age: 60.1 years, 8 males, 12 females) were included. Ocular symptoms were improved after treatment for 1 month in all patients (ocular symptom score pre-treatment 76.83 vs 46.75 after treatment; P<0.001). There was no statistically significant difference in lid margin abnormality score or tear meniscus amount. The Schirmer test results were improved after treatment for 3 months (pre- and after treatment, 6.70 vs 11.40; P<0.001).
CONCLUSIONS: Topical cyclosporine A 0.05% showed a satisfactory effect in long-standing prosthetic eye wearers. Ocular symptoms were markedly relieved in all subjects after treatment for 1 month.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25081289      PMCID: PMC4194340          DOI: 10.1038/eye.2014.174

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  35 in total

1.  Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops.

Authors:  D BenEzra; N Matamoros; E Cohen
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

2.  A survey of satisfaction in anophthalmic patients wearing ocular prosthesis.

Authors:  Jong-Suk Song; Jaeryung Oh; Se Hyun Baek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-17       Impact factor: 3.117

3.  Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A.

Authors:  F Brignole; P J Pisella; M De Saint Jean; M Goldschild; A Goguel; C Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-01       Impact factor: 4.799

4.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.

Authors:  K Sall; O D Stevenson; T K Mundorf; B L Reis
Journal:  Ophthalmology       Date:  2000-04       Impact factor: 12.079

5.  Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.

Authors:  Steven E Wilson; Henry D Perry
Journal:  Ophthalmology       Date:  2006-10-27       Impact factor: 12.079

6.  The use of topical cyclosporin A in ocular graft-versus-host-disease.

Authors:  E Kiang; N Tesavibul; R Yee; J Kellaway; D Przepiorka
Journal:  Bone Marrow Transplant       Date:  1998-07       Impact factor: 5.483

7.  [Complications from eye prosthesis].

Authors:  Marie Louise Roed Rasmussen
Journal:  Ugeskr Laeger       Date:  2008-08-11

8.  Conjunctival cytologic features in anophthalmic patients wearing an ocular prosthesis.

Authors:  Jong Hyun Kim; Min Joung Lee; Ho-Kyung Choung; Nam Ju Kim; Sang-won Hwang; Mi Sun Sung; Sang In Khwarg
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2008 Jul-Aug       Impact factor: 1.746

9.  Immunologic and clinical evaluation of postsurgical necrotizing sclerocorneal ulceration.

Authors:  D Díaz-Valle; J M Benítez del Castillo; A Castillo; O Sayagués; A Bañares; J García-Sánchez
Journal:  Cornea       Date:  1998-07       Impact factor: 2.651

10.  Cost of dry eye treatment in an Asian clinic setting.

Authors:  Samanthila Waduthantri; Siew Sian Yong; Chien Hua Tan; Liang Shen; Man Xin Lee; Sangeetha Nagarajan; Mynt Htoon Hla; Louis Tong
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

View more
  1 in total

1.  Effect of topical loteprednol etabonate with lid hygiene on tear cytokines and meibomian gland dysfunction in prosthetic eye wearers.

Authors:  J S Ko; Y Seo; M K Chae; S Y Jang; J S Yoon
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.